This is why … “AstraZeneca” stops testing “Corona vaccine”

0
42


The end of August announced the start of experiments with antibodies

The “AstraZeneca” pharmaceutical group announced that it has decided to “voluntarily suspend” clinical trials that it is conducting around the world for an experimental vaccine against Covid-19 disease developed by the University of Oxford; And this is after one of the participants in these experiments contracted a disease for no apparent reason.

The group said in a statement that “within the framework of the global randomized clinical trials of the Oxford Coronavirus vaccine, our standard evaluation process has been activated and we have voluntarily suspended the vaccinations to allow for a review of safety data by an independent committee.”

At the end of August, AstraZeneca announced the start of trials with antibodies to treat “Covid-19” disease, caused by the new Corona virus.

AstraZeneca said it has begun testing an antibody-based treatment to prevent and treat Covid-19 disease. Indicating that the first participants in the experiments took doses of it.

The British company added that the first phase of the trials will focus on evaluating whether the drug “AZD 7442”, which includes two types of monoclonal antibodies, is safe and tolerated by the body among up to 48 healthy participants between the ages of 18 and 55 years. ; According to the agency “Reuters”.

And if the first experiments to be conducted in Britain showed positive results; AstraZeneca will embark on a broader phase of drug testing as a preventative treatment and as a medicine for patients who have contracted it.

In June, the company, listed on the London Stock Exchange, received $ 23.7 million in funding from agencies of the US government to develop antibiotic-based treatments for Covid-19.

Previous clinical trials on volunteers had shown that the “AstraZeneca” vaccine for the “Covid-19” epidemic was safe and generated immunity among those who received it.

The vaccine, named “AZD1222”, did not cause any side effects, did not harm the antibodies, and the “T cells” response, according to the results published in the “Lancet” medical journal; According to “Reuters”.

The University of Oxford, which is developing the vaccine in cooperation with AstraZenka, said that experiments showed that the volunteers who received the second dose appeared to have antibodies, and they also developed T cells that help strengthen the immune system in the human body.

The new corona virus

For this reason .. “AstraZeneca” stops testing “Corona vaccine”

Previously

The “AstraZeneca” pharmaceutical group announced that it has decided to “voluntarily suspend” clinical trials that it is conducting around the world for an experimental vaccine against Covid-19 disease developed by the University of Oxford; And this is after one of the participants in these experiments contracted a disease for no apparent reason.

The group said in a statement that “within the framework of the global randomized clinical trials of the Oxford Coronavirus vaccine, our standard evaluation process has been activated and we have voluntarily suspended the vaccinations to allow for a review of safety data by an independent committee.”

At the end of August, AstraZeneca announced the start of trials with antibodies to treat “Covid-19” disease, caused by the new Corona virus.

AstraZeneca said it has begun testing an antibody-based treatment to prevent and treat Covid-19 disease. Indicating that the first participants in the experiments took doses of it.

The British company added that the first phase of the trials will focus on evaluating whether the drug “AZD 7442”, which includes two types of monoclonal antibodies, is safe and tolerated by the body among up to 48 healthy participants between the ages of 18 and 55 years. ; According to the agency “Reuters”.

If the first tests to be conducted in Britain showed positive results; AstraZeneca will embark on a broader phase of drug testing as a preventative treatment and as a medicine for patients who have contracted it.

In June, the company, listed on the London Stock Exchange, received $ 23.7 million in funding from agencies of the US government to develop antibiotic-based treatments for Covid-19.

Previous clinical trials on volunteers had shown that the “AstraZeneca” vaccine for the “Covid-19” epidemic was safe and generated immunity among those who received it.

The vaccine, named “AZD1222”, did not cause any side effects, did not harm the antibodies, and the “T cells” response, according to the results published in the “Lancet” medical journal; According to “Reuters”.

The University of Oxford, which is developing the vaccine in cooperation with AstraZenka, said that experiments showed that the volunteers who received the second dose appeared to have antibodies, and they also developed T cells that help strengthen the immune system in the human body.

09 September 2020 – 21 Muharram 1442

09:20 AM


The end of August announced the start of experiments with antibodies

The “AstraZeneca” pharmaceutical group announced that it has decided to “voluntarily suspend” clinical trials that it is conducting around the world for an experimental vaccine against Covid-19 disease developed by the University of Oxford; And this is after one of the participants in these experiments contracted a disease for no apparent reason.

The group said in a statement that “within the framework of the global randomized clinical trials of the Oxford Coronavirus vaccine, our standard evaluation process has been activated and we have voluntarily suspended the vaccinations to allow for a review of safety data by an independent committee.”

And AstraZeneca had announced at the end of August the start of trials with antibodies to treat “Covid-19” disease, caused by the new Corona virus.

AstraZeneca said it has begun testing an antibody-based treatment to prevent and treat Covid-19 disease. Indicating that the first participants in the experiments took doses of it.

The British company added that the first phase of the trials will focus on evaluating whether the drug “AZD 7442”, which includes two types of monoclonal antibodies, is safe and tolerated by the body among up to 48 healthy participants between the ages of 18 and 55 years. ; According to the agency “Reuters”.

If the first tests to be conducted in Britain showed positive results; AstraZeneca will embark on a broader phase of drug testing as a preventative treatment and as a medicine for patients who have contracted it.

In June, the company, listed on the London Stock Exchange, received $ 23.7 million in funding from agencies of the US government to develop antibiotic-based treatments for Covid-19.

Previous clinical trials on volunteers had shown that the “AstraZeneca” vaccine for the “Covid-19” epidemic was safe and generated immunity among those who received it.

The vaccine, named “AZD1222”, did not cause any side effects, did not harm the antibodies, and the “T-cells” response, according to the results published in the “Lancet” medical journal; According to “Reuters”.

The University of Oxford, which is developing the vaccine in cooperation with AstraZenka, said that experiments showed that the volunteers who received the second dose appeared to have antibodies, and they also developed T cells that help to strengthen the immune system in the human body.

LEAVE A REPLY

Please enter your comment!
Please enter your name here